PDE5A and prostate carcinoma: Similarly, the meta-analysis from Candy B, et al [35] showed oral PDE5-Is were effective in the medium term (up to 4 months) when used to treat ED subsequent to external beam radiotherapy or radical bilateral nerve-sparing or unilateral nerve sparing RP for prostate cancer.